Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Abstract

Anti-HER2 immunoliposomes produced enhanced antitumor efficacy via targeted delivery.

Keywords

DoxorubicinLiposomePharmacologyIn vivoDrug deliveryMedicinePharmacokineticsTrastuzumabMonoclonal antibodyTargeted drug deliveryTherapeutic indexDrugChemistryChemotherapyCancerAntibodyImmunologyBreast cancerBiochemistryBiologyInternal medicine

Affiliated Institutions

University of California, San Francisco US

Related Publications

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

Detection of Surface Antigen 17-1A in Breast and Colorectal Cancer

Jens Packeisen , CH. KAUP-FRANZEN , H.‐J. Knieriem

Substantial progress has been made in detecting cell surface or intracytoplasmatic antigens to identify spread tumor cells with monoclonal antibodies (MAbs). The 17-1A antigen i...

1999 Hybridoma 34 citations

Publication Info

Year: 2002
Type: article
Volume: 8
Issue: 4
Pages: 1172-81
Citations: 648
Access: Closed

External Links

Citation Metrics

648

OpenAlex

Cite This

APA Style

                            
                                    John W. Park, 
                                
                                    Keelung Hong, 
                                
                                    Dmitri B. Kirpotin
                                
                                et al.
                            
                            (2002). 
                            Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.. 
                            PubMed
                            , 8
                            (4)
                            , 1172-81.